

Alexander L Khokhlov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2409759/publications.pdf>

Version: 2024-02-01

45
papers

10,022
citations

394421

19
h-index

361022

35
g-index

47
all docs

47
docs citations

47
times ranked

11887
citing authors

#	ARTICLE	IF	CITATIONS
1	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	27.0	4,215
2	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 323-334.	27.0	2,809
3	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , 2018, 392, 1519-1529.	13.7	1,179
4	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	27.0	510
5	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016, 37, 2882-2889.	2.2	222
6	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017, 103, 307-314.	2.9	205
7	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	3.7	127
8	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <i>PLoS ONE</i> , 2016, 11, e0164076.	2.5	118
9	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <i>BMJ Open</i> , 2017, 7, e017157.	1.9	92
10	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018, 13, e0191592.	2.5	80
11	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S12-20.	2.2	74
12	Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study. <i>Nutrition Research</i> , 2009, 29, 298-304.	2.9	48
13	Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee. <i>Advances in Therapy</i> , 2010, 27, 731-742.	2.9	48
14	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. <i>American Heart Journal</i> , 2019, 213, 35-46.	2.7	45
15	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	3.7	44
16	Efficacy and safety of flavocoxid compared with naproxen in subjects with osteoarthritis of the knee: a subset analysis. <i>Advances in Therapy</i> , 2010, 27, 953-962.	2.9	31
17	Impact of gender on event rates at 1-year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , 2017, 7, e014579.	1.9	30
18	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018, 39, 464-473.	2.2	28

#	ARTICLE	IF	CITATIONS
19	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 526.	6.1	26
20	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.5	16
21	Stroke prevention in patients from Latin American countries with nonvalvular atrial fibrillation: Insights from the GARFIELD-AF registry. <i>Clinical Cardiology</i> , 2019, 42, 553-560.	1.8	16
22	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. <i>British Journal of Haematology</i> , 2016, 174, 610-623.	2.5	13
23	Effects of the lercanidipine-enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension. <i>Journal of Hypertension</i> , 2016, 34, 139-148.	0.5	10
24	Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus®): a randomized open-label clinical trial. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 263-273.	1.4	5
25	Efficacy and safety of GP40021 insulin lispro biphasic compared with Humalog Mix 25 in Type 2 diabetes mellitus patients. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 55-66.	1.4	3
26	Development of Clinical Pharmacology in the Russian Federation. <i>Clinical Therapeutics</i> , 2016, 38, 1218-1226.e1.	2.5	2
27	Risk management strategy for preventing the reduced treatment effectiveness from the position of drug interactions and polypharmacy in patients with coronary heart disease. <i>Research Results in Pharmacology</i> , 2020, 6, 85-92.	0.4	2
28	Methodical approaches to bioassay of phenolic hydroxylenes contain substances. <i>Medical News of North Caucasus</i> , 2017, 12, .	0.1	2
29	Modeling of Pharmacokinetic Profiles of Insulin Aspart and Biphasic Insulin Aspart 30 / 70. <i>Journal of Clinical Pharmacology</i> , 2022, , .	2.0	2
30	Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19. <i>Farmakoeconomika</i> , 2021, 14, 16-27.	1.2	1
31	The complex characteristics of the statins efficiency in ischemic stroke. <i>Medical News of North Caucasus</i> , 2017, 12, .	0.1	1
32	INFLUENCE OF SEX DIFFERENCES ON PHARMACOKINETICS OF DRUGS WITHIN THE FRAMEWORK OF BIOEQUIVALENCE STUDIES OF GENERIC MEDICINAL PRODUCTS. <i>Acta Biomedica Scientifica</i> , 2018, 3, 94-105.	0.2	1
33	The results of experimental studies of the use of silver nanoparticles in tuberculosis drug-resistant pathogen. <i>Medical News of North Caucasus</i> , 2019, 14, .	0.1	1
34	Enzyme-Linked Immunosorbent Assay Method Application in the Study of Comparative Pharmacokinetics of Insulin Glargin Preparations. <i>Acta Biomedica Scientifica</i> , 2019, 4, 93-101.	0.2	1
35	Quantitative Determination of Mycophenolic Acid in Human Blood Plasma by High-Performance Liquid Chromatography with Tandem Mass-Spectrometric Detection. <i>Pharmaceutical Chemistry Journal</i> , 2017, 51, 504-507.	0.8	0
36	Investigation Planning and Bioequivalence evaluation of Angiotensin II Receptor Antagonists. <i>Pharmaceutical Chemistry Journal</i> , 2019, 53, 680-684.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Industrial Pharmacy: The Way to Create a Product (Monograph Review). Pharmaceutical Chemistry Journal, 2020, 54, 544-546.	0.8	0
38	Methodical approaches to bioassay of substances containing unstable functional groups. Research Results in Pharmacology, 2018, 4, 33-42.	0.3	0
39	Эффективность и безопасность применения препарата «Телзап АМ» (Телмисартан/амлодипин) у пациентов с артериальной гипертензией. Фармацевтический журнал, 2020, 54, 544-546.	0.8	0
40	Эффективность и безопасность применения препарата «Телзап АМ» (Телмисартан/амлодипин) у пациентов с артериальной гипертензией. Фармацевтический журнал, 2020, 54, 544-546.	0.8	0
41	Planning and evaluation of bioequivalence study of HMG-CoA reductase inhibitor. Medical News of North Caucasus, 2020, 15, .	0.1	0
42	Review of bioequivalence studies of cholecalciferol drugs. Research Results in Pharmacology, 2020, 6, 21-26.	0.4	0
43	Pharmacokinetic and Bioequivalence Study of Telzap AM [®] (Telmisartan/amlodipine Fixed-dose) in Healthy Subjects. Drug Development and Registration, 2020, 9, 155-163.	0.6	0
44	Study of the availability of gene therapeutic drugs in the Russian Federation. Remedium Journal About the Russian Market of Medicines and Medical Equipment, 2021, , 69-75.	0.1	0
45	Modeling the Effect of Tocilizumab on The Case Fatality Rate In Patients With Severe Covid-19. International Journal of Pharmaceutical Research (discontinued), 2020, 12, .	0.1	0